Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.


Journal Article

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.

Full Text

Duke Authors

Cited Authors

  • Streiff, MB; Holmstrom, B; Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Wang, T-F; Yee, GC; Zakarija, A; McMillian, N; Engh, AM

Published Date

  • September 2015

Published In

Volume / Issue

  • 13 / 9

Start / End Page

  • 1079 - 1095

PubMed ID

  • 26358792

Pubmed Central ID

  • 26358792

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0133


  • eng

Conference Location

  • United States